1. Home
  2. FTHM vs BOLD Comparison

FTHM vs BOLD Comparison

Compare FTHM & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fathom Holdings Inc.

FTHM

Fathom Holdings Inc.

BUY

Current Price

$1.07

Market Cap

31.5M

Sector

Finance

ML Signal

BUY

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.42

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTHM
BOLD
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
31.5M
36.5M
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
FTHM
BOLD
Price
$1.07
$1.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$2.50
$4.00
AVG Volume (30 Days)
3.8M
63.3K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
32.71
32.47
EPS
N/A
N/A
Revenue
$420,477,000.00
N/A
Revenue This Year
$11.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.45
N/A
52 Week Low
$0.40
$0.96
52 Week High
$3.37
$1.68

Technical Indicators

Market Signals
Indicator
FTHM
BOLD
Relative Strength Index (RSI) 74.49 50.23
Support Level $0.85 $1.40
Resistance Level $1.18 $1.53
Average True Range (ATR) 0.11 0.05
MACD 0.07 -0.00
Stochastic Oscillator 65.05 38.46

Price Performance

Historical Comparison
FTHM
BOLD

About FTHM Fathom Holdings Inc.

Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: